A Broadly Neutralizing Human Anti-HIV Monoclonal Antibody (10E8) Capable of Neutralizing Most HIV-1 Strains
Posted Apr 30 2012 8:00pm
Description of Invention: This Human Anti-HIV Monoclonal Antibody (10E8) has great potential to provide passive protection from infection, as a therapeutic vaccine, or as a tool for the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated thus far and it can potently neutralize up to 98% of genetically diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein, GP41. It is anticipated that 10E8 could be used in combination with another human anti-HIV-1 monoclonal antibody to provide an antibody response that neutralizes nearly all strains of HIV-1. Additionally, 10E8 is a useful tool for the design of vaccine immunogens that can elicit an adaptive immune response to produces 10E8 like antibodies. This technology also includes monoclonal antibodies from the same germ line as 10E8.
Passive protection to prevent HIV infection
Passive protection to prevent mother-to-infant HIV transmission
Topical microbicide to prevent HIV infection
Gene-based vectors for anti-gp41 antibody expression
Therapeutic for the elimination of HIV infected cells that are actively producing virus
One of the most potent Human broadly-neutralizing anti HIV antibodies isolated to date
Broad reactivity and high affinity to most HIV-1 strains
Activity is highly complementary to existing broadly neutralizing antibodies, such as CD4 binding site antibodies
Capable of neutralizing all HIV-1 strains, if used in combination with another anti-HIV monoclonal antibody
Related Technologies: PCT, Application No. PCT/US2006/005613 filed 17 Feb 2006, Reference No. E-123-2005/1 US, Application No. 13/057,414 filed 03 Feb 2011, Reference No. E-291-2008/0 US, Application No. 61/086,098 filed 04 Aug 2008, Reference No. E-291-2008/0
Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine immunogens capable of eliciting a 10E8-like adaptive immune response. For collaboration opportunities, please contact Bill Ronnenberg at 301-451-3522 or email@example.com .